TSPO and myeloid sarcoma: A prior study carried out by Sridharan et al. [60] showed that the TSPO ligand XBD173 competitively displaced [18F]GE-180 in brain tissue of MS patients; hence, the uptake into MS lesions might be specific after all [59,60].